Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.30 |
| ▸ | CTH | P32929 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391315 | 1.00 | EPHX1 (0.35) | EPHX1TP53KDM4EGMNNLMNA | |
| Hydrochloric Acid SCHEMBL5387672 | 0.98 | KDM4E (0.35) | EPHX1TP53KDM4EGMNNLMNA | |
| Hydrochloric Acid SCHEMBL5392336 | 0.98 | KDM4E (0.35) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5384783 | 0.98 | EPHX1 (0.32) | EPHX1TP53KDM4EGMNNLMNA | |
| Hydrochloric Acid SCHEMBL5389051 | 0.97 | KDM4E (0.33) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5393749 | 0.82 | EPHX1 (0.35) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL6900479 | 0.81 | DDAH1 (0.33) | DDAH1CTH | |
| SCHEMBL6885068 | 0.81 | DDAH1 (0.33) | DDAH1CTH | |
| SCHEMBL7424718 | 0.81 | DDAH1 (0.33) | DDAH1CTH | |
| SCHEMBL7177530 | 0.80 | DDAH1 (0.31) | DDAH1CTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-11-03 | — | — | US | claimed |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | claimed |
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | UNIVERSITY OF OTAGO (NZ) | 2020-10-15 | — | — | US | claimed |
| EP-3694832-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | Douglas Pharmaceuticals Limited (NZ) | 2020-08-19 | — | — | EP | claimed |
| US-10744094-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2020-08-18 | — | — | US | claimed |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-07-25 | — | — | US | claimed |
| WO-2019073408-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2019-04-18 | — | — | WO | claimed |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-04-11 | — | — | US | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | claimed |
| US-6518289-B1 | Especially irritable bowel syndrome | PFIZER, INC. | 2003-02-11 | — | — | US | claimed |
| US-20020077342-A1 | Heterocyclic derivatives useful as pharmaceutical agents | WARNER-LAMBERT COMPANY | 2002-06-20 | — | — | US | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| WO-2002036118-A2 | HETEROCYCLIC DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-10 | — | — | WO | claimed |
| EP-1201240-A2 | Heterocyclic derivatives useful as pharmaceutical agents | WARNER-LAMBERT COMPANY (US) | 2002-05-02 | — | — | EP | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| JP-2002508362-A | — | — | 2002-03-19 | — | — | JP | claimed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | claimed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | EPHX1 2819/4885TP53 1913/4885KDM4E 3350/4885 |
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | EPHX1 2097/4885TP53 4813/4885KDM4E 2753/4885 |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | EPHX1 2097/4885TP53 4813/4885KDM4E 2753/4885 |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | EPHX1 2097/4885TP53 4813/4885KDM4E 2753/4885 |
| US-20020077342-A1 | Heterocyclic derivatives useful as pharmaceutical agents | CNR1, SUCNR1, CACNA1A | EPHX1 236/4885TP53 4736/4885KDM4E 2434/4885 |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | EPHX1 2097/4885TP53 4813/4885KDM4E 2753/4885 |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | CRH, HTR5A, HTR6 | EPHX1 1995/4885TP53 4803/4885KDM4E 2202/4885 |
| US-10744094-B2 | Extended release pharmaceutical formulation | CRH, HTR5A, HTR6 | EPHX1 1995/4885TP53 4803/4885KDM4E 2202/4885 |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | CRH, HTR5A, HTR6 | EPHX1 1995/4885TP53 4803/4885KDM4E 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.